Considering gemcitabine-based combination chemotherapy as a potential treatment for advanced oesophageal cancer: A meta-analysis of randomised trials.
Administration, Intravesical
Antimetabolites, Antineoplastic
/ therapeutic use
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Deoxycytidine
/ analogs & derivatives
Disease Progression
Drug Administration Schedule
Esophageal Neoplasms
/ drug therapy
Female
Humans
Neoplasm Recurrence, Local
/ prevention & control
Randomized Controlled Trials as Topic
Gemcitabine
Journal
International journal of clinical practice
ISSN: 1742-1241
Titre abrégé: Int J Clin Pract
Pays: India
ID NLM: 9712381
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
12
03
2020
revised:
30
03
2020
accepted:
06
04
2020
pubmed:
13
4
2020
medline:
18
11
2020
entrez:
13
4
2020
Statut:
ppublish
Résumé
Gemcitabine has been proved to be effective in many advanced cancer. However, almost all trials failed to demonstrate the response rate of gemcitabine-based combination schedules on oesophageal cancer (EC). A systematic meta-analysis of randomised clinical trials (RCTs) was performed to investigate the efficacy of gemcitabine-based combination chemotherapy in EC treatment. Clinical trials were collected during the period ranging from January 2000 to November 2018 by searching different databases. Odds-ratios (ORs) of response rate (RR), disease control rate (DCR) and grade 3-4 toxicity rates (TRs) were extracted as presented in retrieved studies. Fourteen trials (1024 patients) were selected for the final analysis. The results showed that RR and DCR of gemcitabine-based combination chemotherapy demonstrated a significant advantage for non-gemcitabine therapy (OR for RR: 1.51; 95% CI: 1.16-1.96; P = .002; OR for DCR: 1.66; 95% CI: 1.19-2.32, P = .003). Toxicities of gemcitabine-based combination chemotherapy on gastrointestinal tract (OR, 0.39; 95% CI: 0.24-0.63, P = .0001) were less frequent compared to that of the non-gemcitabine therapy. The improvements of gemcitabine-based combination chemotherapy on RR, CDR and reduction of gastrointestinal tract, hepatic and renal for EC patients suggests that the combined chemotherapy based on gemcitabine could be a potential treatment options for advanced EC.
Sections du résumé
BACKGROUND
BACKGROUND
Gemcitabine has been proved to be effective in many advanced cancer. However, almost all trials failed to demonstrate the response rate of gemcitabine-based combination schedules on oesophageal cancer (EC).
METHODS
METHODS
A systematic meta-analysis of randomised clinical trials (RCTs) was performed to investigate the efficacy of gemcitabine-based combination chemotherapy in EC treatment. Clinical trials were collected during the period ranging from January 2000 to November 2018 by searching different databases. Odds-ratios (ORs) of response rate (RR), disease control rate (DCR) and grade 3-4 toxicity rates (TRs) were extracted as presented in retrieved studies.
RESULTS
RESULTS
Fourteen trials (1024 patients) were selected for the final analysis. The results showed that RR and DCR of gemcitabine-based combination chemotherapy demonstrated a significant advantage for non-gemcitabine therapy (OR for RR: 1.51; 95% CI: 1.16-1.96; P = .002; OR for DCR: 1.66; 95% CI: 1.19-2.32, P = .003). Toxicities of gemcitabine-based combination chemotherapy on gastrointestinal tract (OR, 0.39; 95% CI: 0.24-0.63, P = .0001) were less frequent compared to that of the non-gemcitabine therapy.
CONCLUSION
CONCLUSIONS
The improvements of gemcitabine-based combination chemotherapy on RR, CDR and reduction of gastrointestinal tract, hepatic and renal for EC patients suggests that the combined chemotherapy based on gemcitabine could be a potential treatment options for advanced EC.
Substances chimiques
Antimetabolites, Antineoplastic
0
Deoxycytidine
0W860991D6
Gemcitabine
0
Types de publication
Journal Article
Meta-Analysis
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13510Subventions
Organisme : Shanxi Province Science Foundation for Youths
ID : 201701D221255
Organisme : Shanxi Province Science Foundation for Youths
ID : 201701D221258
Organisme : Research Foundation for the Doctorial Program of Shanxi Medical University
ID : 03201558
Organisme : Scientific and Technologial Innovation Programs of Higher Education Institutions in Shanxi
ID : 2019L0441
Informations de copyright
© 2020 John Wiley & Sons Ltd.
Références
Sharma P, Saraya A, Sharma R. Abstract B43: evaluation of a miRNA-mRNA panel for esophageal cancer detection. Can Res. 2016;76(6 Suppl):B43.
Agrawal N, Jiao Y, Bettegowda C, et al. Comparative genomic analysis of esophageal adenocarcinoma and squamous cell carcinoma. Can Dis. 2012;2(10):899-905.
Kim J-H, Chung HS, Youn YH, et al. Treatment outcomes of 70 cases of early esophageal carcinoma: 12 years of experience. Dis Esophagus. 2010;20(4):297-300.
Pöttgen C, Stuschke MS. Radiotherapy versus surgery within multimodality protocols for esophageal cancer - a meta-analysis of the randomized trials. Cancer Treat Rev. 2012;38(6):599-604.
Chen C, Chen M, Benhua XU. Efficacy of induction chemotherapy combined with concurrent chemo-radiotherapy for advanced esophageal cancer. China Modern Doctor. 2016;54(33):68-71.
Morgan-Meadows S, Mulkerin D, Berlin JD, et al. A phase II trial of gemcitabine, 5-fluorouracil and leucovorin in advanced esophageal carcinoma. Oncology. 2005;69(2):130-134.
Dong X, Zhao X, Peng C, et al. A comparing trial of gemcitabine plus carboplatin versus etoposide plus carboplatin in treatment of patients with advanced esophageal cancer. Chin J New Drugs Clin Rem. 2007;26(3):225-228.
Liu D. A comparing trial of the efficacy of different chemotherapy regimens and prognosis factor analysis in treatment of patients with advanced esophageal squamous cell carcinoma. Doctoral dissertation. 2006.
Shang D, Yin S, Ji H, et al. Analysis of the clinical efficacy and safety of docetaxel or gemcitabine combined with S-1 as second-line chemotherapy for advanced esophageal squamous cell cancer. Oncol Prog. 2017;15(4):405-407.
Sun Y. Clinical observation of gemcitabine combined with cisplatin in the treatment of advanced esophageal cancer. Chin J Traumatol. 2013;21(7):200-201.
Sun Z. Gemcitabine and docetaxel combined with oxaliplatin for advanced stage clinical analysis of esophageal squamous cell carcinoma. J Medical Forum. 2017;38(6):141-142.
Wang X, Qin C. Clinical observation of gemcitabine combined with oxaliplatin in the treatment of advanced esophageal cancer. Chin Prac Med. 2011;6(9):139-140.
Wang X, Lin M, Gao Z. Clinical efficacy of cyclophosphamide and capecitabine combined with gemcitabine in the treatment of esophageal cancer. Med Equip. 2016;29(1):152-153.
Wu F, Wang K, Huang W, Wang M. Clinical observation of gemcitabine combined with oxaliplatin compared with docetaxel combined with oxaliplatin in the treatment of patients with advanced esophageal cancer. Mod Oncol. 2014;22(3):566-568.
Yan X, Xia X, Liu Q, Fang H, Baim L. Comparative analysis of gemcitabine or fluorouracil combined with cisplatin as second-line treatment of advanced esophageal squamous cell carcinoma. Acad J Chin PLA Med Sch. 2015;36(6):607-610.
Yin H, Wang B, Ji Y, et al. Effect of gemcitabine combined with oxaliplatin in the treatment of elderly patients with advanced esophageal cancer. J Hainan Med. 2012;23(2):27-28.
Yuan L. Efficacy of gemcitabine combined with cisplatin in treating advanced esophageal cancer. Chin Med Phar. 2013;3(8):61-62.
Zhang H. Efficacy evaluation of radiotherapy combined with gemcitabine in the treatment of locally advanced esophageal cancer in the elderly. Chin J Mod Drug Appl. 2015;9(15):144-145.
Zhu J. Efficacy and safety of gemcitabine combined with nedaplatin in the treatment of advanced esophageal cancer. World Health Dig Med Periodieal. 2012;9(31):89-90.
Zhang L, Zheng Y, Zhuagn M, et al. Clinical analysis of gemcitabine combined with cisplatin in the treatment of advanced esophageal carcinoma. Clin Expert. 2012;32(11):925-928.
Liu L, Liu Z. Clinical observation on gemcitabine plus oxaliplatin for advanced esophageal cancer and cardiac cancer. Chin J Canr Pre Treat. 2006;13(22):1747-1748.